FibroBiologics Inc 2026年季度报告

FibroBiologics, Inc.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting companyor an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒On April 30, 2026, 5,208,915 shares of FibroBiologics, Inc.’s Common Stock, $0.00001 par value per share, were outstanding. FibroBiologics, Inc.Quarterly Report on Form 10-QFor the Quarter Ended March 31, 2026Table of ContentsPART I — FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)4Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20254Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 20255Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31,2026 and 20256Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20257Notes to the Unaudited Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk23Item 4.Controls and Procedures23PART II — OTHER INFORMATIONItem 1.Legal Proceedings25Item 1A.Risk Factors25Item 2.Unregistered Sales of Equity Securities and Use of Proceeds29Item 3.Defaults Upon Senior Securities29Item 4.Mine Safety Disclosures29Item 5.Other Information29Item 6.Exhibits30Signature31 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q, or Quarterly Report, and the documents incorporated by reference herein, if any, contain forward-lookingstatements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained inSection 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, asamended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report, including statementsregarding our future results of operations and financial position, business strategy, prospective products, product approvals, research anddevelopment costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results ofanticipated products and prospects, planned research programs, preclinical studies, clinical trials, manufacturing, and market opportunities areforward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause ouractual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or impliedby the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,”“estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of theseterms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in thisQuarterly Report include, but are not limited to, statements about: •the timing, progress and results of preclinical studies and clinical trials for our current and future product candidates, includingstatements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during whichthe results of the trials will become available and our research and development programs; •the timing and progress of manufacturing of our drug product candidates;•the timing, scope or likelihood of regulatory submissions, filings, and approvals, including final regulatory approval of our productcandidates;•our ability to develop and adv